Reversible sideroblastic anemia associated with the tetracycline analogue COL-3

Am J Hematol. 2001 May;67(1):51-3. doi: 10.1002/ajh.1076.

Abstract

Eight of 35 patients with cancer receiving COL-3, a tetracycline derivative with antiangiogenic properties, developed anemia while on treatment. All of these patients were enrolled on an approved Phase I clinical trial at the National Cancer Institute. Three of these patients had bone marrow examinations that revealed ringed sideroblasts. This paper describes these cases. Am. J. Hematol. 67:51-53, 2001. Published 2001 Wiley-Liss, Inc.

Publication types

  • Case Reports
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adenocarcinoma, Follicular / complications
  • Adenocarcinoma, Follicular / drug therapy
  • Adult
  • Anemia, Sideroblastic / chemically induced*
  • Antibiotics, Antineoplastic / administration & dosage
  • Antibiotics, Antineoplastic / adverse effects
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / adverse effects
  • Bone Marrow / pathology
  • Female
  • Humans
  • Male
  • Middle Aged
  • Tetracycline / administration & dosage
  • Tetracycline / adverse effects*
  • Tetracyclines
  • Thyroid Neoplasms / complications
  • Thyroid Neoplasms / drug therapy

Substances

  • Antibiotics, Antineoplastic
  • Antineoplastic Agents
  • Tetracyclines
  • tetracycline CMT-3
  • Tetracycline